CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response

Junho Kang, Jae Ho Jeong, Hee-Sang Hwang, Sang Soo Lee, Do Hyun Park, Dong Wook Oh, Tae Jun Song, Ki-Hun Kim, Shin Hwang, Dae Wook Hwang, Song Cheol Kim, Jin-hong Park, Seung-Mo Hong, Kyu-pyo Kim, Baek-Yeol Ryoo, Changhoon Yoo

Cancer Research and Treatment. 2020;52(2):594-603. Published online 2019 December 18 DOI: https://doi.org/10.4143/crt.2019.493

Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response

Cancer Research and Treatment. 2020;52(2):594-603

Link1

Link2 Link3

Efficacy and Safety of S-1 as Second-Line Chemotherapy for Patients with Advanced Biliary Tract Cancer

S. Kobayashi, M. Ueno, S. Ohkawa, T. Andou, R. Kameda

Annals of Oncology. 2012;23:xi121

Link1 Link2

In response to She et al., “Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater”

Min Huang, Ralph P. Insinga, Thomas Burke, Ying Zhang, Gilberto de Lima Lopes

Lung Cancer. 2020;146:385-386

Link1 Link2

Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine

Masafumi Ikeda, Tatsuya Ioka, Akira Fukutomi, Chigusa Morizane, Akiyoshi Kasuga, Hideaki Takahashi, Akiko Todaka, Takuji Okusaka, Caretha L. Creasy, Shelby Gorman, Daniel J. Felitsky, Mikiro Kobayashi, Fanghong Zhang, Junji Furuse

Cancer Science. 2017;109(1):215-224

Link1 Link2

Su1143 EFFICACY AND SAFETY OF PEMBROLIZUMAB FOR GEMCITABINE/CISPLATIN-REFRACTORY BILIARY TRACT CANCER: A MULTICENTER RETROSPECTIVE STUDY

Sang Hoon Lee, Hee Seung Lee, Seungmin Bang, Sang Hyub Lee, Sang Myung Woo, Dong Uk Kim

Gastroenterology. 2020;158(6):S-522-S-523

Link1 Link2

Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study

Sang Hoon Lee, Hee Seung Lee, Sang Hyub Lee, Sang Myung Woo, Dong Uk Kim, Seungmin Bang

Journal of Clinical Medicine. 2020;9(6):1769

Link1

525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028

Y.J. Bang, T. Doi, F. De Braud, S. Piha-Paul, A. Hollebecque, A.R. Abdul Razak, C.C. Lin, P.A. Ott, A.R. He, S.S. Yuan, M. Koshiji, B. Lam, R. Aggarwal

European Journal of Cancer. 2015;51:S112

Link1 Link2

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program

Markus Moehler, Annett Maderer, Anne Ehrlich, Friedrich Foerster, Arno Schad, Tanja Nickolay, Christian Ruckes, Arndt Weinmann, Visvakanth Sivanathan, Jens U. Marquardt, Peter Robert Galle, Marcus Woerns, Thomas Thomaidis

BMC Cancer. 2019;19(1):

Link1

Link2 Link3

High PD-L1 expression is associated with treatment response to pembrolizumab in patients with advanced biliary tract cancer

G. Kim, S. Ahn, J.-H. Hwang, J.-C. Lee, J. Kim

Annals of Oncology. 2019;30:v279-v280

Link1 Link2 Link3

High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer

Soomin Ahn, Jong-chan Lee, Dong Woo Shin, Jaihwan Kim, Jin-Hyeok Hwang

Scientific Reports. 2020;10(1):

Link1

Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.